Clinical trials: DASATINIB

Waldenstrom Macroglobulinemia, DASATINIB

Dasatinib In Waldenström Macroglobulinemia

• Terminated
• Age: 18 years and older
• Phase 1
• Pill or oral medicine
• Results posted

This is Phase I pilot, single center study designed to explore the safety of Dasatinib in symptomatic Waldenström Macroglobulinemia participants who are progressing on ibrutinib therapy with BTK Cys481 or PLCG2 mutations

Trial name

NCT04115059

Testing

Dasatinib

Where

United States

Volunteers

3 people

Sponsor

Jorge J. Castillo, MD